Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 132

Proximal median nerve neuropathy: electrodiagnostic and ultrasound findings in 62 patients

Objectives: Proximal median nerve (PMN) neuropathies are caused by lesions proximal to the carpal tunnel, which include the forearm, elbow, upper arm, and brachial plexus. Differentiating between carpal tunnel syndrome and PMN neuropathies is important to guide management and is based on clinical, electrodiagnostic (EDX), and ultrasound (US) findings. This study describes the clinical, EDX, and US features in 62 patients with PMNs.

Methods: All patients underwent EDX studies, and 52 (83.9%) had a US study. The patients were assigned to one of the following four localization zones of PMN neuropathies based on clinical and EDX criteria: Zone 1: extends from the fascicles in the brachial plexus contributing to the median nerve to the innervation of the pronator teres (PT); Zone 2: distal to the branch to the PT and proximal to the origin of the anterior interosseous nerve (AIN); Zone 3: involves the origin of the AIN; and Zone 4: distal to the origin of the AIN and proximal to the carpal tunnel. The localization was based on the pattern of muscle weakness, topography of EMG abnormalities, and US study findings.

Results: The anatomical locations of the PMN neuropathies based on clinical, EDX, and US findings were as follows: Zone 1 in 38 patients (61.3%), Zone 2 in 6 patients (9.7%), Zone 3 in 7 patients (11.3%), and Zone 4 in 11 patients (17.7%). The most common etiology among all 62 patients was iatrogenic injury (30 [48.4%]), followed by non-iatrogenic trauma (20 [32.2%]). The following EDX findings were noted: prolonged distal motor latency (29 [46.8%]), decreased motor nerve conduction velocity in the forearm (22 [35.5%]), low amplitude or absent compound muscle action potentials (50 [80.6%]), and abnormal or absent sensory nerve action potentials (50 [80.6%]). Of the 52 (83.9%) patients who underwent US studies, a total of 22 (42.3%) patients showed an increased cross-sectional area of the median nerve.

Systemically injectable therapy could prevent heart failure after a heart attack

Scientists at Northwestern University and University of California San Diego have developed a new, potent injectable therapy that can protect the heart from damage after a heart attack.

The therapeutic approach comprises specially designed polymers that act like proteins. These protein-like polymers (PLPs) “grab” onto regulatory proteins, which blunt the body’s natural healing process, in heart tissue. With those proteins out of the way, the healing proteins are free to do their job — preventing stress and inflammation.

Protein-like polymer demonstrated improved heart health in animal experiments.

Heart attacks cause long-term damage that ultimately leads to heart failure. New treatment protects the heart from long-term damage after a heart attack.

Cell therapy: The evolution of the ‘living drug’

For decades, researchers have been exploring ways to harness the power of the immune system to treat cancer. One breakthrough is cell therapy, often called ‘living drugs.’ This is a form of immunotherapy that uses immune cells from a patient or a healthy donor. With advanced engineering techniques, scientists enhance these cells to recognize better and attack cancer.

“During the late 1980s and 1990s, cancer researchers started exploring ways to advance immunotherapy by transferring immune cells into a patient to attack cancer cells,” says stem cell transplant and cellular therapy specialist Hind Rafei, M.D. “They recognized that immune cells found inside tumors could help destroy cancer cells, leading to the development of one of the earliest forms of cell therapy — tumor-infiltrating lymphocytes (TILs).”

Cell therapy is a form of immunotherapy that uses immune cells from a patient or a healthy donor to treat cancer. Learn about the types of cell therapy from stem cell transplant and cellular therapy specialist Hind Rafei, M.D.

Handheld device could transform heart disease screening

Researchers have developed a handheld device that could potentially replace stethoscopes as a tool for detecting certain types of heart disease.

The researchers, from the University of Cambridge, developed a device that makes it easy for people with or without medical training to record heart sounds accurately. Unlike a stethoscope, the device works well even if it’s not placed precisely on the chest: its larger, flexible sensing area helps capture clearer heart sounds than traditional stethoscopes.

The device can also be used over clothing, making it more comfortable for patients – especially women – during routine check-ups or community heart health screening programmes.